- Home
- / Candel Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Candel Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$5.5
2024-10-29
Market Capitalization
$176.8 M
2024-10-29
Revenue
$125 K
FY, 2022
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 125.0K | 125.0K | |||
| General and administrative expense | 10.7M | 14.1M | 13.9M | 14.1M | 17.8M |
| Operating expense total | 34.8M | 38.4M | 38.6M | 48.3M | |
| EBIT | (25.7M) | (34.7M) | (38.4M) | (33.4M) | (48.3M) |
| EBIT margin, % | -27777.6% | ||||
| Investment income | (53.0K) | (490.0K) | |||
| Interest income | 2.1M | 1.1M | 3.9M | ||
| Interest expense | 2.6M | 2.1M | |||
| Pre tax profit | (38.2M) | ||||
| Net Income | (36.1M) | (18.8M) | (37.9M) | (55.2M) | (38.2M) |
| EPS | (0.6) | (1.3) | (1.7) | (0.7) |